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Introduction 
Fibrates, including fenofibrate and bezafibrate, are 
commonly used in clinical practice to treat lipid disor-
ders. Fibrates monotherapy is effective for the treatment 
of hypertriglyceridemia, while the combination of a 
fibrate with a statin is an option in the management of 
atherogenic dyslipidemia (Katsiki et al., 2013; Tenen-
baum and Fisman, 2012). 
2-oxoglutarate dehydrogenase (2-OGDH) together with 
pyruvate dehydrogenase and branched chain - keto-
acid dehydrogenase (BCKDH) belong to the family of 
mitochondrial 2-oxoacid dehydrogenases. These com-
plexes have a very similar structure and they all cata-
lyze the decarboxylation of their respective 2-oxoacids.  
2-OGDH catalyzes the irreversible oxidative decarboxy-
lation of 2-oxoglutarate (2-OG), in the presence of 
coenzyme A (CoA) and NAD+ with the formation of the 
succinyl-CoA, CO2 and NADH. The complex consists of 
three catalytic components: 2-oxoglutarate dehydroge-
nase (E1), dihydrolipoamide succinyl transferase (E2) 
and the dihydrolipoamide dehydrogenase (E3). 
Recently a novel component, Kgd4, necessary to a form 
a stable complex has been identified (Heublein et al., 
2014). 
It has been found that fibrates affect liver BCKDH com-
plex activity (Ono et al., 1990). This effect is especially 
pronounced in protein-malnourished animals. Fibrates 
up-regulate liver BCKDH activity and promote branch-
ed-chain amino acids catabolism. Stimulation of liver 
BCKDH activity has been observed not only for high 
but also for low, more clinically relevant doses of fibra-
tes. Fibrates may also alter mRNA levels for BCKDH 
components, though this effect depends on the dose 
administered (Knapik-Czajka and Jaskiewicz, 2003; 
Knapik-Czajka et al., 2009; Knapik-Czajka, 2013; 
Kobayashi et al., 2002). To our best knowledge the effect 
of fibrates on liver 2-OGDH complex has not been 
studied yet. The present study has been undertaken to 
investigate the in vivo effect of low, clinically relevant 
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Abstract 
Multienzyme 2-oxoglutarate complex (2-OGDH) together with branched 
chain -ketoacid dehydrogenase (BCKDH) and pyruvate dehydrogenase  
belong to the family of mitochondrial 2-oxoacid dehydrogenases. Hypolipi-
demic drugs, bezafibrate and fenofibrate, up-regulate liver BCKDH. The 
present study has been undertaken to determine the effect of low doses of 
bezafibrate and fenofibrate on liver 2-OGDH. Fibrates were administrated to 
rats fed low-protein diet at 5, 10 or 20 mg/kg. In rats treated with increasing 
doses of bezafibrate 2-OGDH activity increased by 7, 35 and 42%, while in 
rats administered with fenofibrate by 8, 18, and 56% (p<0.05 for bezafibrate 10 
and 20, and fenofibrate 20 mg/kg). Changes in 2-OGDH activity did not 
correspond with changes in mRNA levels of the complex enzymes. Moreover, 
mRNA levels of PPAR  remained unaltered. It is conceivable that stimulation 
of 2-OGDH activity by low doses of fibrates is the result of post-transcrip-
tional events and may have a significant effect on liver metabolism.  
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doses of bezafibrate and fenofibrate (5, 10 and 20 mg/
kg/day) on liver 2-OGDH complex activity as well as 
E1 and E2 mRNA levels in the liver tissue of rats fed 
low-protein diet. In addition, PPAR  abundance has 
been measured. 
 
Materials and Methods 
Reagents: All chemicals used in the experiments were 
purchased from Sigma–Aldrich Chemical Company 
(Germany). Low-protein diet (8% protein) was bought 
from MP Biomedicals (USA). RevertAid™ H Minus 
First Strand cDNA Synthesis Kit was purchased from 
Fermentas (Germany) and Perpetual OptiTaq DNA 
polymerase from Erex (Poland). 
Animals and experimental treatment: Animal experiments 
were conducted in accordance with the guidelines for 
animal experiments of Animal Research Committee and 
were approved by the Jagiellonian University Ethic 
Committee. Male Wistar rats (from inbred strain) were 
purchased from the breeding facility of the Jagiellonian 
University Faculty of Pharmacy. They were housed 
four per cage and maintained under standardized 
conditions of artificial 12-hours light/dark cycle and 
constant room temperature (21–23°C). All rats were fed 
low-protein diet (8% protein content) ad libitum and 
allowed free access to water. After acclimatization to 
low-protein diet and the oral administration of 0.3% 
dimethylcellulose (agent's vehicle) rats were randomi-
zed into 7 treatment groups (n=4). Group 1 (control 
group): rats administered with 0.3% dimethylcellulose 
solution (agent’s vehicle). Groups 2, 3 and 4: rats treated 
with bezafibrate at the dose of 5 mg/kg, 10 mg/kg and 
20 mg/kg, respectively. Groups 5, 6 and 7: rats treated 
with fenofibrate at the dose of 5 mg/kg, 10 mg/kg and 
20 mg/kg, respectively. Bezafibrate or fenofibrate were 
administered intragastrically for 14 days (once daily). 
Then liver tissues were excised, weighted and imme-
diately freeze-clamped with aluminum tongs precooled 
in liquid nitrogen and then stored at −80°C until 
analysis. 
Determination of liver 2-OGDH activity: Tissue extracts 
for the assay of liver 2-OGDH were prepared as descri-
bed previously (Blair et al., 1999). Briefly, a portion of 
frozen liver was powdered in liquid nitrogen, weighed 
and homogenized in an extraction buffer. 2-OGDH was 
then concentrated from the whole tissue extracts by 
precipitation with 9% polyethylene glycol. 2-OGDH 
activity (in the presence of thiamine diphosphate in the 
assay cocktail) was determined spectrophotometrically 
at 30°C by measuring the rate of NADH generation 
from NAD+ (340 nm) using the saturating concentration 
of -ketoglutaric acid, a substrate for 2-OGDH complex 
(Cary 100 spectrophotometer– Varian). One unit of 2-
OGDH complex activity is defined as the amount of 
enzyme that catalyzed the formation of 1 μmol of 
NADH/min.  
Determination of mRNA levels: Relative levels of specific 
mRNAs were assessed by semi-quantitative reverse 
transcription–polymerase chain reaction (RT-PCR). 
Each gene was amplified together with a housekeeping 
gene -actin (internal control). Total liver RNA was 
isolated with TRI reagent (Sigma–Aldrich, Germany) 
and cDNA was subsequently synthesized using 1μg 
total RNA, reverse-transcriptase and oligo dT primers 
(RevertAid™ H Minus First Strand cDNA Synthesis 
Kit, Fermentas, Germany). cDNA was amplified with 
OptiTaq DNA polymerase (Eurx, Poland) following 
manufacturer's instructions. Each PCR reaction was 
performed with rat-specific primers that were designed 
for the genes of interest using Primer-BLAST software 
(NCBI) (Table I). After an initial denaturation at 95°C, 
PCR was carried out for 35 cycles. Each cycle consisted 
of denaturation at 96°C for 15 sec, primer annealing at 
65°C for 30 sec (E1) or at 60°C (E2, PPAR , -actin) and 
primer extension at 72°C for 45 sec. The PCR products 
were subjected to agarose gel electrophoresis (1.5% 
agarose gel), stained with ethidium bromide and analy-
zed by densitometry using the Quantity One software 
(Bio Rad). Obtained data were first normalized to -
actin (in the same sample) and then expressed relative 
to the control group (vehicle-treated rats). Relative 
expression level of particular mRNA in each fibrate-
treated group was presented using arbitrary units (% of 
control group).  
Statistics: Statistical calculations were performed using 
the GrandPad Prism version 5.0 (GraphPad Software, 
Inc., San Diego, CA). Data are presented as mean ± 
SEM. Differences between groups were determined 
with one-way analysis of variance (ANOVA), followed, 
when appropriate, by Bonferroni post hoc test, with 
acceptable significance levels set at p<0.05.  
 
Results 
Both bezafibrate and fenofibrate administered to 
protein-restricted rats stimulated liver 2-OGDH activity 
in a dose-dependent manner (Figure 1A and 1B). In rats 
that received 5, 10 and 20 mg/kg bezafibrate 2-OGDH 
activity increased by 7%, 35% and 42% in comparison to 
untreated group, respectively. The difference was 
statistically significant for the doses of 10 and 20 mg/kg 
(p<0.001). 
In fenofibrate-treated rats liver 2-OGDH activity was 
8%, 18% and 56% higher than in the control group. The 
difference was statistically significant for rats given the 
highest dose of fenofibrate (p<0.001).  
The effect of bezafibrate on E1 and E2 subunit mRNA 
levels is presented in Figure 2A and 2B. Mean E1 
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mRNA levels in rats given 5 and 10 mg/kg bezafibrate 
did not differ from untreated rats (101 ± 2% and 100 ± 3 
vs 100 ± 2% for bezafibrate treated and control group, 
respectively), whereas in the group that received the 
highest dose of bezafibrate mRNA E1 abundance 
decreased by 4% (p>0.05). Bezafibrate administration 
slightly increased E2 mRNA level (105 ± 1%, 107 ± 2% 
and 107 ± 3% vs 100 ± 2% for the control group). The 
difference was not statistically significant (p>0.05).  
In rats treated with 5 and 10 mg/kg fenofibrate mRNA 
level for E1 was 3% and 4% lower, whereas in rats 
administered with the highest dose (20 mg/kg) 2% 
higher than in the control group (p>0.05) (Figure 3A). 
Mean mRNA abundance of E2 increased insignificantly 
in response to fenofibrate administration (107 ± 2%, 106 
± 2% and 106 ± 2% vs 100 ± 2% for treated and the 
control group, respectively; p>0.05) (Figure 3B).  
There was no significant difference in the mean liver 
mRNA abundance for PPAR  between bezafibrate-
treated groups and control rats (99 ± 4%, 99 ± 4% and 
101 ± 3% vs. 100 ± 4% for the control group) (Figure 
4A). mRNA levels for PPAR  in rats administered with 
increasing doses of fenofibrate were 7%, 3% and 5% low
-er than in vehicle-treated animals (p>0.05) (Figure 4B).  
Table I 
Primer sequences used in RT-PCR  
Gene amplified 
(product bp) 
Primer Sequence Primer concentration 
(pmol/µL) 
E1 
(347) 
5’- GGA GAC AGG TAT TTG TGG AAG GC -3’ 
5’- CCA GGG AGC TTC GAC TCA GG -3’ 
4 
4 
E2 
(339) 
5’- AGA TGT CAG GTG GGA GAA AG -3’ 
5’- GGT TTG CTA GAA GGA GGT TG -3’ 
4 
4 
PPAR  
(510) 
5’- TCA GAG GTC CCT GAA CAG TG -3’ 
5’- AAG CCA TCT TCA CGA TGC TG -3’ 
2 
2 
-actin 
(228) 
5’-AGCCATGTACGTAGCCATCC-3’ 
5’CTCTCAGCTGTGGTGGTGAA-3’ 
4 
4 
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Figure 1: Effect of increasing doses of bezafibrate (1A) and fenofibrate (1B) on 2-OGDH activity in rat’s liver 
Rats were fed low-protein diet and administered with 5, 10 or 20 mg/kg/day of bezafibrate or given only the vehicle (control group - 0 g/kg/day 
bezafibrate or fenofibrate). Data are presented as mean ± SEM (n=4); *p<0.001 compared to the control group 
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Discussion  
Results of the present study indicate that administra-
tion of some low doses of bezafibrate and fenofibrate to 
rats fed with low-protein diet caused stimulation of 
liver 2-OGDH activity. However, changes in 2-OGDH 
activity did not correspond with changes in catalytic 
subunit (E1 and E2) mRNA levels. In addition, there 
was no difference in the number of PPAR transcripts 
between fibrates-treated and control rats. Therefore, it is 
possible that elevated 2-OGDH activity upon fibrates 
administration is the result of PPAR -independent post
-transcriptional events. Our finding is in accordance 
with results obtained by (Prager et al., 1993). They have 
found that high experimental dose of clofibrate (diet 
containing 0.75% of clofibrate), a parent compound of 
fibrates, enhanced 2-OGDH activity in rat’s liver. It 
appears that low doses of bezafibrate and fenofibrate 
administered to protein-malnourished rats have a 
similar effect on liver 2-OGDH activity as high 
experimental doses of clofibrate.  
The influence of pharmacological agents on different 
metabolic processes may vary with dosage, with an 
agent showing an effect when used in a high experi-
mental dose, and having no effect when used in a low 
dose. Most of the research on biological effects of 
fibrates has been performed using higher doses than 
those in clinical use. Results of the present and previous 
studies have indicated that clinically relevant doses of 
fibrates increase 2-OGDH and BCKDH activities in rats 
fed low-protein diet. Stimulation of liver BCKDH by 
fibrates was mainly due to increased dephosphory-
lation (and thus activation of the complex) and was not 
associated with changes in mRNA levels for BCKDH 
catalytic and regulatory enzymes (Knapik-Czajka et al., 
2009; Knapik-Czajka, 2013). It has well been known that 
unlike BCKDH the activity of 2-OGDH is not regulated 
by reversible phosphorylation. However, some recent 
data have indicated that the oxidative decarboxylation 
of 2-OG can nevertheless be regulated by phosphory-
lation, albeit by a different mechanism (Lagranha et al., 
2010; Niebisch et al., 2006). In view of this finding it 
Figure 2: Effect of increasing doses of bezabrate on liver E1 (2A) and E2 (2B) mRNA levels 
Rats were fed low-protein diet and administered with 5, 10 or 20 mg/kg b.wt/day of bezafibrate or given only the vehicle (control group - 0 g/kg 
b.wt/day bezafibrate). The levels of E1 and E2 mRNA were quantitated by densitometry then normalized to β-actin mRNA (in the same sample) and 
expressed relative to the control rats (arbitrary units- % of control). Upper panel: representative agarose gel; Lower panel: bar graph displaying the 
mean values ± SEM  
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cannot be excluded that fibrates increase 2-OGDH acti-
vity by modifying the phosphorylation of the complex.  
We can hypothesize that activation of 2-OGDH by 
tested fibrates is due to changes in some factors regu-
lating 2-OGDH complex. 2-OGDH activity depends on 
substrate availability and is allosterically inhibited by 
increased succinyl-CoA/CoA and NADH/NAD+ ratios 
(McMinn and Ottaway, 1977; Smith et al., 1974). It has 
been shown that in rat’s liver clofibrate decreases succi-
nyl-CoA level and increases the concentration of free 
CoA leading to the reduction of succinyl-CoA/CoA 
ratio (Ball et al., 1979). It is conceivable that clofibrate 
analogs, fenofibrate and bezafibrate, have a similar 
effect on succinyl-CoA/CoA ratio. 
Previous studies have established that calcium increa-
ses 2-OGDH activity by reducing Km for its substrate, 2
-OG (Denton, 2009; Lawlis and Roche, 1981). It has also 
been found that in HepG2 hepatoma cell line calcium 
concentration increases in response to the fenofibrate 
treatment. Therefore, it seems likely that stimulation of 
liver 2-OGDH by fibrates may be partly related to 
changes in intracellular calcium levels (Jiao and Zhao, 
2002).  
Furthermore, it cannot be excluded that fibrates stimu-
late 2-OGDH by changing the activity of Kgd4 or other 
currently unidentified protein factors that regulate the 
assembly of functional 2-OGDH complex. 
Fibrates action at the molecular level is mostly associa-
ted with the regulation of transcription of genes enco-
ding for different proteins, particularly those that con-
trol lipid metabolism. This process is mediated by per-
oxisome proliferator-activated receptors (PPAR) which 
belong to a group of nuclear receptor proteins that 
function as transcription factors (Fruchart et al., 1999). 
PPAR family includes three isoforms: ,  (also called 
) and . Fenofibrate binds to PPAR , while bezafibrate 
is an agonist for all three PPAR isoforms. In addition, 
fibrates regulate different metabolic processes in PPAR-
independent manner (Chanda et al., 2009; Shimomura 
et al., 2006). 
Figure 3: Effect of increasing doses of fenofibrate on liver E1 (3A) and E2 (3B) mRNA levels 
Rats were fed low-protein diet and administered with 5, 10 or 20 mg/kg/day of fenofibrate or given only the vehicle (control group - 0 g/kg/day 
fenofibrate). The levels of E1 and E2 mRNA were quantitated by densitometry then normalized to -actin mRNA (in the same sample) and expressed 
relative to the control rats (arbitrary units-% of control). Upper panel: representative agarose gel; Lower panel: bar graph displaying the mean values 
± SEM  
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Low doses of bezafibrate and fenofibrate adminstered 
to rats fed with low-protein diet did not affect mRNA 
levels for PPAR . This finding is in agreement with 
results obtained by (Nakajima et al., 2008; Nakajima et 
al., 2009) who have shown that administration of low 
dose of bezafibrate is not associated with changes in 
mRNA levels for PPAR . They have also presented the 
hypothesis that lipid lowering action of clinically 
relevant doses of bezafibrate is mediated by mecha-
nisms other than PPAR  activation. 
The metabolic consequences of decreased 2-OGDH acti-
vity have been extensively studied, mostly in nervous 
tissue. It is well documented that reduced activity of 2-
OGDH contributes to development of some neurodege-
nerative diseases (Gibson et al., 2012). In contrast, data 
on the changes in metabolism induced by 2-OGDH 
stimulation are scarcely available (Graf et al., 2013). It is 
probable that increased 2-OGDH activity modifies liver 
metabolism because the complex plays an important 
role in the regulation of different biochemical 
pathways.2-OGDH as a key enzyme of tricarboxylic 
acid cycle exerts a control on overall oxidative/energy 
metabolism. The complex activity is crucial for 
maintenance of the mitochondrial redox state 
(expressed as NADH/NAD+ ratio) and energy produc-
tion. 2-OGDH regulates ATP generation by providing 
NADH (which oxidation is linked to formation of ATP 
from ADP) and by providing succinyl-CoA (for 
substrate-level phosphorylation). Therefore, stimulation 
of 2-OGDH activity by fibrates may lead to changes in 
mitochondrial metabolism and overall cell functions. 
2-OGDH is one of major factors determining some 
amino acids, mainly glutamate synthesis (Araujo et al., 
2013). 2-OGDH competes with glutamate dehydro-
genase, a key enzyme of the glutamate biosynthetic 
pathway, for the common substrate, 2-OG. It is conceiv-
able that increased 2-OGDH activity upon fibrates 
administration may lead to decreased 2-OG levels and 
Figure 4: Effect of increasing doses of bezabrate (4A) and fenofibrate (4B) on liver PPAR  mRNA levels 
Rats were fed low-protein diet and administered with 5, 10 or 20 mg/kg/day of bezafibrate or fenofibrate. Control group was given only the vehicle 
(- 0 g/kg/day bezafibrate or fenofibrate). The level of PPAR  mRNA was quantitated by densitometry then normalized to -actin mRNA (in the 
same sample) and expressed relative to the control rats (arbitrary units- % of control). Upper panel: representative agarose gel; Lower panel: bar 
graph displaying the mean values ± SEM  
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modify glutamate metabolism.  
Gibson et al., (2015) have demonstrated that 2-OGDH 
acts as a trans-succinylase that mediates succinylation 
of different proteins, including other enzymes of the 
tricarboxylic acid cycle. It has been found that succiny-
lation of various proteins is one of the most important 
signaling systems in the cells. It is possible that stimu-
lation of 2-OGDH in response to fibrates administration 
can affect signal transmission in liver.  
In conclusion, obtained results indicate that in rats fed 
with low-protein diet some low, clinically relevant 
doses of bezafibrate and fenofibrate increase liver 2-
OGDH activity without affecting mRNA levels for cata-
lytic enzymes of the complex. The effect of fibrates is 
not associated with changes in PPAR  levels. Taking 
into consideration the crucial role of 2-OGDH in the 
regulation of various metabolic processes it is concei-
vable that increased 2-OGDH activity can affect overall 
liver metabolism. Further studies are required to fully 
elucidate the molecular mechanism of fibrates action 
and metabolic consequences of increased activity of 2-
OGDH complex in the liver of rats fed low-protein diet.  
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